Infliximab as a treatment for systemic amyloidosis associated with Crohn's disease

Secondary Amyloidosis in a Patient with Long Duration Crohnʼs Disease Treated with Infliximab

“…[2] Amyloid formation in Crohn's disease, as well as in other chronic inflammatory diseases, results from the proteolytic cleavage of the circulating acute-phase reactant serum amyloidwith extracellular deposition of AA protein in tissues, causing organ dysfunction. It is believed that, for amyloid fibrils to deposit in tissues causing organ damage, there has to be a sustained acute phase response.…”

Efficacy of scheduled infliximab maintenance therapy on systemic amyloidosis associated with crohnʼs disease

“…Recent studies show the efficacy of infliximab on secondary amyloidosis associated with rheumatic inflammatory diseases. 3,4 However, only a few case reports, including ours, [5][6][7] have shown the therapeutic effects of infliximab on CD-associated amyloidosis. In addition, it is unclear whether scheduled infliximab maintenance therapy can maintain good renal function of such CD patients.…”

“…Consequently, AA-type amyloid deposition was systemically detected in the biopsy specimens from his colon, terminal ileum, and kidney. On the basis of our previous experience, 5 where infliximab significantly ameliorated the renal function of the patient with CDassociated amyloidosis, we administered infliximab to this patient. In February 2008, infliximab was initiated at a dosage of 5 mg/kg at weeks 0, 2, and 6, and approximately every 8 weeks thereafter.…”

Nephrotic Syndrome after Infliximab Treatment in a Patient with Ulcerative Colitis

“…Renal amyloidosis or drug toxicity was discussed to explain this situation. The renal biopsy was negative for amyloidosis and several case reports have described the efficacy of anti-TNF-α treatment on amyloid nephropathy complicating long-standing Crohn's disease, a treatment which induces a rapid response in proteinuria and a suppression of the renal disease activity [1][2][3][4][5][6].…”